Long-term follow-up of 415 patients with chronic lymphocytic leukaemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials, a comprehensive assessment of prognostic factors
Name:
American J Hematol - 2022 - ...
Size:
554.6Kb
Format:
PDF
Description:
From UNPAYWALL
Authors
Allsup, D.Craig, Z.
Cairns, D.
Howard, D.
Hockaday, A.
Bloor, A.
Soe, Z.
Pepper, C.
Gattei, V.
Zucchetto, A.
Robbe, P.
Clifford, R.
Schuh, A.
Munir, T.
Rawstron, A.
Hillmen, P.
Affiliation
Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, UK. Clinical Trials Research Unit, University of Leeds, Leeds, UK. The Christie NHS Foundation Trust, Manchester, UK. St James Institute of Oncology, Leeds, UK. Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK. Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy. Laboratory for Transcriptome Technology, RIKEN Centre for Integrative Medical Sciences, Yokohama, Japan. Department of Haematology, University Hospital Limerick, Limerick, Ireland. Department of Oncology, University of Oxford, Oxford, UK. Haematological Malignancy Diagnostic Service, St James Hospital, Leeds, UK. Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.Issue Date
2022
Metadata
Show full item recordCitation
Allsup DJ, Craig Z, Cairns D, Howard D, Hockaday A, Bloor A, et al. Long‐term follow‐up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors. American Journal of Hematology. Wiley; 2022.Journal
American Journal of HematologyDOI
10.1002/ajh.26483PubMed ID
35108412Additional Links
https://dx.doi.org/10.1002/ajh.26483Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1002/ajh.26483
Scopus Count
Collections
Related articles
- Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
- Authors: Howard DR, Munir T, McParland L, Rawstron AC, Chalmers A, Gregory WM, O'Dwyer JL, Smith A, Longo R, Varghese A, Smith A, Hillmen P
- Issue date: 2017 May
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
- Authors: Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group
- Issue date: 2010 Oct 2
- Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
- Authors: Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV
- Issue date: 2019 Nov
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
- Authors: Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M, international group of investigators, German CLL Study Group (GCLLSG)
- Issue date: 2016 Jul
- Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
- Authors: Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, Shvidel L, Tadmor T, Ariel A, Braester A, Shapiro M, Joffe E, Polliack A, Israeli CLL Study Group
- Issue date: 2015 May